Beaumont Pharma Limited 12518247 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of the wholesale of pharmaceutical goods Digita Accounts Production Advanced 6.30.9574.0 true 12518247 2024-04-01 2025-03-31 12518247 2025-03-31 12518247 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2025-03-31 12518247 core:CurrentFinancialInstruments 2025-03-31 12518247 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 12518247 bus:SmallEntities 2024-04-01 2025-03-31 12518247 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 12518247 bus:FullAccounts 2024-04-01 2025-03-31 12518247 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 12518247 bus:RegisteredOffice 2024-04-01 2025-03-31 12518247 bus:CompanySecretaryDirector1 2024-04-01 2025-03-31 12518247 bus:Director3 2024-04-01 2025-03-31 12518247 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-04-01 2025-03-31 12518247 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 12518247 countries:England 2024-04-01 2025-03-31 12518247 2023-04-01 2024-03-31 12518247 2024-03-31 12518247 bus:OrdinaryShareClass1 bus:Non-cumulativeShares 2024-03-31 12518247 core:CurrentFinancialInstruments 2024-03-31 12518247 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 12518247

Beaumont Pharma Limited
Annual Report and Unaudited Financial Statements
for the Year Ended 31 March 2025

Beaumont Pharma Limited

Contents

Balance Sheet | 1
Notes to the Unaudited Financial Statements | 2 to 4

Beaumont Pharma Limited

(Registration number: 12518247)
Balance Sheet as at 31 March 2025

| Note | 2025 £ | 2024 £
Current assets |  |  |
Stocks | 4 | 753,921 | 805,185
Debtors | 5 | 827,602 | 603,260
Cash at bank and in hand |  | 309,660 | 254,605
|  | 1,891,183 | 1,663,050
Creditors: Amounts falling due within one year | 6 | (1,423,361) | (1,311,338)
Net assets |  | 467,822 | 351,712
Capital and reserves |  |  |
Called up share capital | 7 | 100 | 100
Retained earnings |  | 467,722 | 351,612
Shareholders' funds |  | 467,822 | 351,712

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and FRS 102 ‘The Financial Reporting Standard Applicable in the UK and Republic of Ireland’.

Approved and authorised by the Board on 13 April 2026 and signed on its behalf by:

......................................... Dr J A Sharples Company secretary and director
......................................... Mrs R N Shafiq Director

Beaumont Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1 | General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Lashbrook Lodge
New Road
Shiplake
RG9 3LH

These financial statements were authorised for issue by the Board on 13 April 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.
Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

Beaumont Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.
The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

3 | Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2024 - 2).

Beaumont Pharma Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

4 | Stocks

| 2025 £ | 2024 £
Other inventories | 753,921 | 805,185

5 | Debtors

| 2025 £ | 2024 £
Trade debtors | 624,321 | 460,323
Other debtors | 203,281 | 142,937
| 827,602 | 603,260

6 | Creditors

| Note | 2025 £ | 2024 £
Due within one year |  |  |
Loans and borrowings |  | 351,124 | 355,688
Trade creditors |  | 738,894 | 573,983
Taxation and social security |  | 283,622 | 241,475
Accruals and deferred income |  | 49,721 | 140,192
|  | 1,423,361 | 1,311,338

7 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary of £1 each | 100 | 100 | 100 | 100